Celularity Inc. (CELU)

Market Cap	25.09M -33.2%
Revenue (ttm)	26.55M -51.0%
Net Income	-91.67M
EPS	-3.59
Shares Out	28.84M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	120,889
Open	0.8800
Previous Close	0.8986
Day's Range	0.8450 - 0.9189
52-Week Range	0.7101 - 4.3500
Beta	0.45
Analysts	Buy
Price Target	25.00 (+2,773.23%)
Earnings Date	Apr 30, 2026

About CELU

Celularity Inc., a regenerative and cellular medicines company, focuses on addressing aging-related and degenerative diseases. It develops off-the-shelf placental-derived allogeneic cell therapy product candidates, including mesenchymal-like adherent stromal cells for diabetic foot ulcer and Crohn’s disease. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. Its therapeutic programs include PDA-001 for the treatment of autoimmune (Crohn’s) and degenerative disease; and PDA-002 for treating facioscap...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Employees: 123
• Stock Exchange: NASDAQ
• Ticker Symbol: CELU
• Website: https://www.celularity.com

Financial Performance

In 2025, Celularity's revenue was $26.55 million, a decrease of -51.03% compared to the previous year's $54.22 million. Losses were -$91.67 million, 58.4% more than in 2024.

Analyst Summary

According to one analyst, the rating for CELU stock is "Buy" and the 12-month stock price target is $25.0.

Price Target

$25.0

(2,773.23% upside)

Analyst Consensus: Buy